GS Paper III · Science & Technology · Biotechnology
🧬 Stem Cell Therapy — Types, Uses & Issues
What is a Stem Cell · Embryonic vs Adult vs iPSC · How Therapy Works · Bone Marrow Transplant · Parkinson's & Diabetes Research · India Regulations · Supreme Court 2026 Autism Ruling · NMC 32 Approved Diseases · Stem Cell Tourism · PYQs & MCQs
🔬
What is a Stem Cell? — The Body's "Master Reset Button"
Core Concept · Non-Bio Student Friendly
📖 Definition
A stem cell is an undifferentiated (unspecialised) cell with two extraordinary abilities: (1) Self-renewal — it can divide and copy itself indefinitely, and (2) Differentiation — it can develop into any of the 200+ specialised cell types in the body (muscle, nerve, blood, bone, etc.). Stem cells are essentially the body's raw material — the original blank pages from which all the different chapters (cell types) are written.
What is a Stem Cell?
A stem cell can either replicate itself (self-renewal) OR differentiate into specialised cells — blood cells, muscle fibres, nerve cells, fat cells, and more.
🧠 Super Simple Analogy — For Non-Biology Students
Think of your body as a country. Most citizens (cells) are specialists — doctors, engineers, farmers. They do one job and can't switch. A stem cell is like a fresh recruit with no specialisation yet — the government (body) can train them to become ANYTHING needed. If an area loses farmers (damaged liver cells), stem cells can be deployed and trained to become farmers (liver cells) to fill the gap.
🔁 Two Key Properties of All Stem Cells
♾
Self-Renewal
Can divide repeatedly — even after long dormancy — maintaining the stem cell pool throughout life. Unlike most cells which divide a limited number of times.
🔀
Differentiation
Can transform into specialised cell types — blood, bone, nerve, muscle, skin. The degree varies: embryonic cells → any cell; adult cells → fewer options.
🏗
Repair & Regeneration
The body uses stem cells as a repair system — replacing cells damaged by injury, disease, or ageing. This is the foundation of stem cell therapy.
🧪
Types of Stem Cells High Yield
Embryonic · Adult · iPSC · Foetal · Cord Blood
🧠 Mnemonic — Remember the Types
"Every Adult Is Pretty Clever"
Embryonic → Adult → Induced Pluripotent → Perinatal (Cord blood) → Cancer stem cells
Embryonic → Adult → Induced Pluripotent → Perinatal (Cord blood) → Cancer stem cells
🥚 Embryonic Stem Cells (ESC)
Potency: PLURIPOTENT — can become ANY cell type
Source: Inner cell mass of a 3–5 day embryo (blastocyst) — obtained from IVF embryos donated for research
Powers: Unlimited self-renewal · Can form all 200+ cell types · Best research tool
⚠ Controversy: Requires destruction of a human embryo → major ethical debate. Banned for many uses in India.
Source: Inner cell mass of a 3–5 day embryo (blastocyst) — obtained from IVF embryos donated for research
Powers: Unlimited self-renewal · Can form all 200+ cell types · Best research tool
⚠ Controversy: Requires destruction of a human embryo → major ethical debate. Banned for many uses in India.
🦴 Adult Stem Cells (ASC)
Potency: MULTIPOTENT — can become several related cell types
Source: Bone marrow, blood, fat tissue, brain, liver — found in small numbers in every organ
Powers: Maintain & repair the tissue in which they are found
✅ Currently APPROVED: Blood stem cells (HSCs) from bone marrow are the only widely approved therapy — used for blood cancers & disorders (thalassaemia, sickle cell, leukaemia)
Source: Bone marrow, blood, fat tissue, brain, liver — found in small numbers in every organ
Powers: Maintain & repair the tissue in which they are found
✅ Currently APPROVED: Blood stem cells (HSCs) from bone marrow are the only widely approved therapy — used for blood cancers & disorders (thalassaemia, sickle cell, leukaemia)
🔬 Induced Pluripotent (iPSC)
Potency: PLURIPOTENT (same as embryonic!)
Source: Adult cells (skin/blood) reprogrammed in lab using Yamanaka factors (4 specific genes)
Powers: Can form any cell type; patient-specific → low rejection risk; No embryo needed → ethically acceptable
Nobel Prize: Shinya Yamanaka (Japan) & John B. Gurdon (UK) shared the Nobel Prize 2012 in Physiology or Medicine for showing mature cells can be reprogrammed to pluripotency — UPSC tested this!
Source: Adult cells (skin/blood) reprogrammed in lab using Yamanaka factors (4 specific genes)
Powers: Can form any cell type; patient-specific → low rejection risk; No embryo needed → ethically acceptable
Nobel Prize: Shinya Yamanaka (Japan) & John B. Gurdon (UK) shared the Nobel Prize 2012 in Physiology or Medicine for showing mature cells can be reprogrammed to pluripotency — UPSC tested this!
🔺 Potency Hierarchy — How Much Can Each Type Become?
🥇 TOTIPOTENT — Most Powerful
Source: Fertilised egg (Zygote) · Days 0–3 embryo
Can become: Every single cell type including placenta → can form an entire organism
Can become: Every single cell type including placenta → can form an entire organism
▼
🥈 PLURIPOTENT
Source: Embryonic Stem Cells (ESC) · Induced Pluripotent (iPSC)
Can become: Any of 200+ body cell types — but NOT the placenta
Can become: Any of 200+ body cell types — but NOT the placenta
▼
🥉 MULTIPOTENT
Source: Adult Stem Cells — HSC (blood), MSC (bone/fat/muscle)
Can become: Several related cell types only — e.g. HSC → all blood cells (red, white, platelets) but NOT nerve or muscle
Can become: Several related cell types only — e.g. HSC → all blood cells (red, white, platelets) but NOT nerve or muscle
▼
4️⃣ UNIPOTENT — Least Powerful
Source: Tissue-specific stem cells (e.g., skin stem cells, liver stem cells)
Can become: Only ONE cell type — skin stem cell → skin cells only
Can become: Only ONE cell type — skin stem cell → skin cells only
Zygote = Totipotent
ESC / iPSC = Pluripotent
HSC / MSC = Multipotent
Skin SC = Unipotent
| Type | Source | Potency | Ethical Status | Current Clinical Use |
|---|---|---|---|---|
| Embryonic (ESC) | IVF embryo (blastocyst) | Pluripotent | ⚠ Controversial — embryo destroyed | Research only in India |
| Adult — HSC | Bone marrow, peripheral blood | Multipotent | ✅ Accepted | ✅ APPROVED — blood cancers, thalassaemia, sickle cell |
| Adult — MSC | Fat tissue, bone marrow | Multipotent | ✅ Accepted | 🔬 Clinical trials (autoimmune, GvHD) |
| iPSC | Adult skin/blood reprogrammed | Pluripotent | ✅ No embryo needed | 🔬 Research & trials (eye — AMD, Parkinson's) |
| Cord Blood (Perinatal) | Umbilical cord blood at birth | Multipotent | ✅ Accepted | ✅ Blood cancers — similar to bone marrow transplant |
| Foetal Stem Cells | Aborted foetal tissue | Multipotent | ⚠ Ethically contested | Research only |
🇮🇳 India Cord Blood Context
Cord Blood Banking — collecting and storing the blood from a newborn's umbilical cord — is growing rapidly in India. Companies like LifeCell, Cordlife, and Cryoviva offer private banking. The cord blood is rich in Haematopoietic Stem Cells (HSCs) which can be used to treat blood diseases later in the child's life. Public cord blood banks (like those promoted by ICMR) are important for social equity — private banking serves only the affluent. This is a relevant UPSC public health policy angle.
💉
Stem Cell Therapy — How It Works & What It Treats
Regenerative Medicine · Current & Future Applications
📖 What is Stem Cell Therapy?
Stem cell therapy (also called regenerative medicine) uses stem cells or their derivatives to repair, replace, or regenerate diseased, dysfunctional, or damaged tissues. Unlike drugs that just manage symptoms, stem cells aim to fix the underlying damage — potentially offering a one-time, long-lasting treatment.
⚙ How Stem Cell Therapy Works — Step by Step
🩸
① Harvest
Stem cells collected from bone marrow, blood, fat tissue, or cord blood
🧫
② Process
Cells separated, tested for purity, sometimes expanded in lab bioreactor
🧬
③ Modify (iPSC)
For iPSC therapy: adult cells reprogrammed to pluripotent state in lab
💉
④ Transplant
Cells infused into patient via IV, or directly implanted into target tissue
🔄
⑤ Engraft & Repair
Stem cells migrate to damaged site, differentiate, and replace lost cells
Haematopoiesis: how Blood Stem Cells (HSC) give rise to all blood cell types — red cells, white cells, platelets. This is the basis of bone marrow transplant therapy. (Source: Wikimedia Commons)
Two main approaches to stem cell therapy: using the patient's own cells (autologous — lower rejection risk) or donor cells (allogeneic — may need immunosuppression). (Source: Wikimedia Commons)
🩺 Current & Future Applications:
| Disease | Stem Cell Type Used | Status | India Angle |
|---|---|---|---|
| Leukaemia & Lymphoma | HSC from bone marrow / cord blood | ✅ APPROVED | AIIMS, Tata Memorial do 1000s of BMTs/year |
| Thalassaemia | HSC (allogeneic bone marrow transplant) | ✅ APPROVED | India has 40 million thalassaemia carriers — major public health issue |
| Sickle Cell Disease | HSC transplant (+ Gene therapy — BIRSA 101) | ✅ APPROVED | PM Modi inaugurated SCD mission — tribal area focus |
| Aplastic Anaemia | HSC bone marrow transplant | ✅ APPROVED | Affordable BMT centres growing across India |
| Severe Burns | Skin stem cells (autologous) | ✅ APPROVED | Skin grafting using cultured stem cells |
| Age-Related Macular Degeneration (AMD) | iPSC-derived retinal cells | 🔬 Clinical Trials | Vision loss in elderly — growing priority |
| Parkinson's Disease | iPSC-derived dopamine neurons | 🔬 Phase I/II Trials | 2025: Safety demonstrated in early trials (in news) |
| Type 1 Diabetes | iPSC-derived pancreatic beta cells | 🔬 Clinical Trials | Vertex's VX-880 (iPSC-derived islets) in Phase I/II trials; cadaveric islet therapy (Lantidra) FDA-approved 2023 for severe T1D but is not stem-cell-based |
| Heart Failure | Mesenchymal stem cells (MSC) | 🔬 Research | Repair of cardiac muscle post-heart attack |
| Spinal Cord Injury | Neural stem cells | 🔬 Research | Paraplegic rehabilitation research at NIMHANS |
| Autism Spectrum Disorder (ASD) | Various — unproven | ❌ BANNED — SC 2026 | Supreme Court Jan 30, 2026 — declared unethical |
| Cerebral Palsy | Various — unproven | ❌ BANNED | NMC March 25, 2026 directive |
🏥 India Current Affairs 2025 — Mumbai Baby Case
Doctors in Mumbai (2025) used mesenchymal stem cell (MSC) therapy on an experimental basis to save the life of a premature baby boy suffering from chronic lung disease. The baby was injected with 40 million stem cells, and gradually the lungs began to repair. This was done under experimental protocols with proper consent — not routine clinical use. This case highlights both the promise and the experimental nature of stem cell therapies beyond approved indications.
🔴 Current Affairs 2025 — Parkinson's Disease Breakthrough
Clinical trials published in 2025 demonstrated the safety of stem cell therapies (iPSC-derived dopamine neurons) for Parkinson's disease. While still early stage (Phase I), patients showed no serious adverse events and some showed neurological stabilisation. This is a major milestone — Parkinson's affects ~10 million globally including ~1 million in India, and currently has no cure — only symptom management. If successful, this could be the first cell-based cure for a major neurodegenerative disease.
🇮🇳
India's Regulatory Framework for Stem Cells
ICMR · CDSCO · New Drugs Rules 2019 · NGSCR 2025
📅 Regulatory Timeline — India
📋
2017
National Guidelines for Stem Cell Research (NGSCR) 2017 — jointly formulated by ICMR & Department of Biotechnology (DBT). Only haematopoietic stem cell transplantation (HSCT) for haematological disorders approved for routine clinical use. All other stem cell therapy = investigational, must be clinical trial only.
⚖
2019
New Drugs and Clinical Trial Rules, 2019 — Union Health Ministry notification. Classified stem-cell-derived products as "new drugs". Any doctor using stem cell therapy must take permission from CDSCO (government). Violators subject to legal action.
🔬
2021
Evidence Based Stem Cell Therapy (EBSSCT) Guidelines 2021 — additional guidance confirming no evidence for stem cell therapy in ASD, cerebral palsy, or most neurological conditions.
📜
2025
National Guidelines for Stem Cell Research (NGSCR) 2025 — updated guidelines by ICMR & DBT. Governs all stem cell research in India. Strengthens oversight of experimental therapies. Basis for the 2026 Supreme Court ruling.
⚖
Jan 30, 2026
Supreme Court Judgment — Yash Charitable Trust & Ors. v. Union of India (W.P. No. 369/2022). Stem cell therapy for ASD declared unethical and illegal outside clinical trials. Directed government to create dedicated regulatory authority for stem cell research.
📢
Mar 25, 2026
NMC Advisory — National Medical Commission directed all medical colleges to restrict stem cell therapy to only 32 approved conditions. Anything outside this list = illegal. Violations = malpractice charges.
🏛
CDSCO
Central Drugs Standard Control Organisation under DCGI — regulates clinical trials & approves stem cell therapies. Approval needed before ANY stem cell research beyond standard care.
🔬
ICMR / DBT
Indian Council of Medical Research + Department of Biotechnology — jointly issue guidelines (NGSCR). All biomedical research must comply with ICMR Ethical Guidelines. Informed consent mandatory.
⚕
NMC
National Medical Commission — regulates doctors and medical colleges. Issues advisories enforcing Supreme Court & ICMR guidelines. Can take action for malpractice against doctors using unapproved therapies.
📋 The 32 Approved Conditions (Key ones to know)
NMC/ICMR restricts routine clinical use to Ministry of Health & Family Welfare-approved indications. Key approved conditions include: Leukaemia, Lymphoma, Myeloma, Aplastic Anaemia, Thalassaemia, Sickle Cell Disease (all using haematopoietic stem cell transplantation) and a few others under strict clinical settings.
NOT approved for routine use: Autism Spectrum Disorder, Cerebral Palsy, Parkinson's, Alzheimer's, Diabetes, Spinal cord injury, Stroke — these require approved clinical trial registration.
NOT approved for routine use: Autism Spectrum Disorder, Cerebral Palsy, Parkinson's, Alzheimer's, Diabetes, Spinal cord injury, Stroke — these require approved clinical trial registration.
⚖
🔴 Supreme Court Landmark Ruling — Jan 30, 2026 Current Affairs
Yash Charitable Trust v. Union of India · Autism · NMC Advisory March 2026
🔴 Breaking — January 30, 2026
The Supreme Court of India (Bench led by Justice Pardiwala) in Yash Charitable Trust & Ors. v. Union of India & Ors. categorically ruled that stem cell therapy for Autism Spectrum Disorder (ASD) cannot be offered as a routine clinical service. Offering unproven stem cell treatments to autistic patients outside approved clinical trials amounts to medical malpractice. The Court directed the Union Government to create a dedicated regulatory authority for stem cell research.
⚖
What the Court Said
• No reliable, conclusive evidence that stem cell therapy is safe or effective for ASD
• Patient/parental consent CANNOT justify scientifically unproven treatments
• Informed consent requires evidence-backed information — absent here
• Using unproven therapies = violation of reasonable standard of care
• Patient/parental consent CANNOT justify scientifically unproven treatments
• Informed consent requires evidence-backed information — absent here
• Using unproven therapies = violation of reasonable standard of care
📋
What the Court Ordered
• Stem cell therapy for ASD banned outside approved clinical trials
• Union Govt must create dedicated stem cell regulatory authority
• ICMR & NMC to enforce compliance across all medical institutions
• Violating doctors liable for malpractice under New Drugs Rules 2019
• Union Govt must create dedicated stem cell regulatory authority
• ICMR & NMC to enforce compliance across all medical institutions
• Violating doctors liable for malpractice under New Drugs Rules 2019
🔴 Follow-Up — March 25, 2026 (NMC Advisory)
Following the Supreme Court judgment, the National Medical Commission (NMC) on March 25, 2026 issued a strict advisory to all medical colleges:
- Stem cell therapy in routine practice: permitted only for 32 approved conditions listed by MoHFW
- Any therapy beyond this list without CDSCO/DHR approval = illegal
- Research requires compliance with ICMR ethical guidelines + written informed consent + no cost to patient
- All biomedical research must be approved by an Institutional Ethics Committee (IEC) registered with DHR
🔗 UPSC Multi-Dimensional Angle
This ruling connects multiple GS papers: GS Paper II (Judiciary, healthcare policy, NMC), GS Paper III (Science & Technology, biotechnology regulation), GS Paper IV (Ethics — informed consent, patient autonomy vs paternalism, evidence-based medicine). The Court's reasoning — that consent cannot override scientific evidence — is a landmark statement on medical ethics and regulatory paternalism.
⚠
Challenges, Ethical Issues & Stem Cell Tourism
Safety · Ethics · IPR · Commercialisation
🧫
Tumour Formation Risk
Pluripotent stem cells (especially iPSC) can form teratomas (tumours containing mixed cell types) if not fully differentiated before transplant. Major safety concern blocking clinical approval.
🛡
Immune Rejection
Allogeneic (donor) stem cells can be rejected by the patient's immune system — similar to organ transplant rejection. Requires lifelong immunosuppression drugs, which have their own side effects.
✈
Stem Cell Tourism
Desperate patients travel to countries with weak regulations (China, Mexico, Germany) for unapproved therapies. Often expensive, unproven, and dangerous. Has caused deaths and permanent disability. India is itself a destination.
⚗
Embryo Ethics
Embryonic stem cell research requires destroying a human embryo → "Is an embryo a person?" debate. Catholic Church, many religions oppose ESC research. India's ICMR allows only surplus IVF embryos with donor consent.
💰
Cost & Access
Bone marrow transplants cost ₹15–40 lakh in India's private hospitals. Even "cheaper" Indian hospitals are beyond reach of most. iPSC therapies in the USA can cost $500,000+. Access equity is a massive challenge.
⚕
Exploitation of Vulnerable
Desperate families of ASD, cancer, or SCI patients are targeted by unscrupulous clinics claiming miracle cures. The combination of desperate patients + profit motive + weak regulation = a humanitarian crisis. SC 2026 ruling directly addresses this.
🌍 Stem Cell Tourism — A Global Problem
Stem cell tourism refers to patients travelling internationally to receive unproven stem cell therapies that are banned or unapproved in their home country. Key facts:
- India is both a source (patients going abroad) and a destination (foreign patients coming to India for cheaper unproven treatments)
- Common "treatments" for: ASD, cerebral palsy, Alzheimer's, SCI, anti-ageing — none proven
- Has caused documented deaths and permanent harm
- The International Society for Stem Cell Research (ISSCR) has global guidelines against unproven therapies
- India's Supreme Court 2026 ruling is seen as a landmark step in combating this within India
🧬 The iPSC vs ESC Ethical Advantage
The Nobel Prize-winning discovery of iPSCs by Shinya Yamanaka (published 2006 / Nobel Prize 2012 shared with John B. Gurdon) was revolutionary precisely because it bypassed the embryo debate. By reprogramming adult skin cells using four transcription factors (Oct4, Sox2, Klf4, c-Myc — now called "Yamanaka factors"), Yamanaka gave scientists a way to get embryonic-like stem cells WITHOUT destroying embryos. This is why iPSC research has exploded globally and has more ethical acceptability than ESC research. For UPSC: iPSC = same power as ESC + no ethical controversy + patient-specific (lower rejection).
📜
PYQs & Practice MCQs
Previous Year Questions + 2026 Current Affairs MCQs
📜 UPSC Prelims 2012 (GS Paper I)
PYQ 2012
Q. With reference to 'stem cells', frequently in the news, which of the following statements is/are correct?
- Stem cells can be derived from mammals only.
- Stem cells can be used for screening new drugs before using them on patients.
- Stem cells can be used to replace or restore damaged or diseased tissues in the body.
- No stem cell therapies other than bone marrow transplant are widely used clinically.
- a) 1, 2 and 3 only
- b) 2, 3 and 4 only ✓
- c) 3 and 4 only
- d) 1, 2, 3 and 4
Explanation: Statement 1 is WRONG — stem cells exist in many organisms beyond mammals (plants, insects, fish). Statements 2, 3, 4 are correct. (2) Stem cells can be used to create disease models for drug testing — replacing animal testing. (3) They can replace damaged tissue — basis of all regenerative medicine. (4) Despite decades of hype, only bone marrow transplant (HSC transplant) is the widely used, approved clinical therapy — all others are still investigational. This remains true in 2026 for most conditions.
📜 Practice Question (Based on UPSC Prelims 2022 Pattern)
Practice Q
Q. "Stem cell therapy is gaining popularity in India." In this context, which of the following statements is/are correct?
- Autologous stem cell therapy uses stem cells from the patient themselves, while allogeneic therapy uses donor stem cells.
- All stem cell therapies currently in use have been proven safe and effective through clinical trials.
- Cord blood is a source of haematopoietic stem cells.
- a) 1 and 3 only ✓
- b) 2 and 3 only
- c) 1, 2 and 3
- d) 3 only
Statement 1 CORRECT: Autologous = patient's own cells (lower rejection risk, no donor needed). Allogeneic = donor cells (more widely available, but requires HLA matching to prevent rejection). Both types are used in bone marrow transplants. Statement 2 WRONG: Many therapies marketed in India are NOT proven — this is exactly the problem the Supreme Court 2026 ruling addresses. Only HSC transplants are fully validated. Statement 3 CORRECT: Umbilical cord blood contains abundant HSCs and is used similarly to bone marrow transplants for blood diseases.
📜 UPSC Mains 2021 — GS Paper III (10 marks)
Mains 2021
Q. Stem cell therapy is gaining popularity in India to treat a wide variety of medical conditions including leukaemia, thalassaemia, damaged cornea, and several burns. Describe briefly what stem cell therapy is and what advantages it has over other treatments? (10 marks)
Model Answer Framework:
Model Answer Framework:
- Introduction: Define stem cells (self-renewal + differentiation) and stem cell therapy (regenerative medicine). Mention approved use (HSC transplant) vs experimental
- Types: Embryonic (pluripotent), Adult HSC/MSC (multipotent), iPSC (pluripotent, Nobel 2012) — briefly explain each with potency
- Current Uses in India: Leukaemia & lymphoma (AIIMS, Tata Memorial) · Thalassaemia · Sickle cell · Aplastic anaemia · Skin grafts for burns · AMD eye therapy
- Advantages: (1) Treats root cause not symptoms (2) Potential one-time cure (3) Autologous cells → no rejection (4) Reduces organ transplant need (5) Drug testing platform
- Challenges: Only HSC transplant proven · Tumour risk · Cost · Stem cell tourism · Ethical concerns (ESC) · Regulation gaps
- India Regulation: NGSCR 2017/2025 (ICMR-DBT) · New Drugs Rules 2019 (CDSCO) · SC 2026 ruling · NMC March 2026 advisory — 32 diseases only
- Conclusion: Immense potential but requires evidence-based regulation, public cord blood banks, and international regulatory harmonisation
🧪 Practice MCQs — Stem Cell Therapy (Click to attempt)
Q1. With reference to Induced Pluripotent Stem Cells (iPSCs), which of the following statements is/are correct?
1. iPSCs require destruction of a human embryo to produce.
2. They have the same potency as embryonic stem cells.
3. Shinya Yamanaka won the Nobel Prize 2012 for their discovery.
1. iPSCs require destruction of a human embryo to produce.
2. They have the same potency as embryonic stem cells.
3. Shinya Yamanaka won the Nobel Prize 2012 for their discovery.
- (a) 1 and 2 only
- (b) 2 only
- (c) 2 and 3 only
- (d) 1, 2 and 3
Statement 1 WRONG — iPSCs are made by reprogramming adult cells (skin or blood) in a laboratory — NO embryo is needed or destroyed. This is their key ethical advantage over embryonic stem cells. Statements 2 & 3 CORRECT — iPSCs are pluripotent (same as ESC — can form any cell type), and Shinya Yamanaka (Japan) shared the Nobel Prize in Physiology or Medicine 2012 with John B. Gurdon (UK) for demonstrating that mature specialised cells can be reprogrammed to become pluripotent. Gurdon's earlier work on nuclear reprogramming in frogs laid the foundation; Yamanaka's 2006 work on iPSCs was the direct discovery.
Q2. The Supreme Court of India in January 2026 banned stem cell therapy for Autism Spectrum Disorder. The Court's primary reasoning was:
- (a) The cost of stem cell therapy is too high for families to afford
- (b) There is no reliable scientific evidence proving stem cell therapy is safe or effective for autism, making its use outside clinical trials unethical and amounting to malpractice
- (c) Stem cell therapy for autism is only available abroad, creating forex drain
- (d) Parental consent was found to be invalid in all cases of autism therapy
The Court held that using stem cell therapy for ASD lacks reliable, conclusive evidence of safety and efficacy. Therefore: (1) genuine "informed consent" is impossible without adequate evidence-based information; (2) patient/parental consent cannot justify treatments that are scientifically unproven; (3) offering such therapy constitutes medical malpractice. The judgment cited ICMR guidelines, EBSSCT 2021, and NGSCR 2017 — all of which uniformly state stem cell therapy is NOT recommended for ASD. The Court also directed government to create a dedicated regulatory authority for stem cell research.
Q3. Which of the following correctly matches stem cell types with their potency?
1. Totipotent — can form any cell including placenta — Fertilised egg
2. Pluripotent — can form any of 200+ body cell types — Embryonic SC & iPSC
3. Multipotent — can form several related types — Adult HSC (blood stem cells)
Select the correct answer:
1. Totipotent — can form any cell including placenta — Fertilised egg
2. Pluripotent — can form any of 200+ body cell types — Embryonic SC & iPSC
3. Multipotent — can form several related types — Adult HSC (blood stem cells)
Select the correct answer:
- (a) 1 and 2 only
- (b) 2 and 3 only
- (c) 1 and 3 only
- (d) 1, 2 and 3
All three are correctly matched. The potency hierarchy (most → least powerful): Totipotent (zygote / day 1–3 embryo — can form entire organism including placenta) → Pluripotent (ESC & iPSC — can form any of 200+ body cell types but NOT placenta) → Multipotent (adult stem cells — can form several related cell types: HSCs → all blood cells; MSCs → bone, cartilage, fat) → Unipotent (skin stem cells → skin only). This hierarchy is a standard UPSC question.
Q4. Consider the following statements about regulations governing stem cell therapy in India:
1. The National Guidelines for Stem Cell Research (NGSCR) were jointly formulated by ICMR and DBT.
2. As per these guidelines, haematopoietic stem cell transplantation (HSCT) for haematological disorders is the only approved routine clinical use.
3. The New Drugs and Clinical Trial Rules 2019 classify stem-cell-derived products as "new drugs" requiring government permission.
Which are correct?
1. The National Guidelines for Stem Cell Research (NGSCR) were jointly formulated by ICMR and DBT.
2. As per these guidelines, haematopoietic stem cell transplantation (HSCT) for haematological disorders is the only approved routine clinical use.
3. The New Drugs and Clinical Trial Rules 2019 classify stem-cell-derived products as "new drugs" requiring government permission.
Which are correct?
- (a) 1 only
- (b) 1 and 2 only
- (c) 2 and 3 only
- (d) 1, 2 and 3
All three correct. (1) NGSCR jointly formulated by ICMR + DBT — first in 2017, updated 2025. (2) Only HSCT (bone marrow transplant) for blood disorders like leukaemia, thalassaemia, aplastic anaemia is approved standard care. All other uses are investigational and require clinical trial registration. (3) New Drugs Rules 2019 — notified by Union Health Ministry — explicitly classifies stem-cell-derived products as "new drugs", meaning any clinical use requires CDSCO (government) permission. Violating doctors can be prosecuted.
Q5. "Stem cell tourism" primarily refers to:
- (a) International conferences on stem cell research where scientists share discoveries
- (b) The practice of wealthy patients travelling abroad to donate stem cells for others
- (c) Patients travelling to countries with weaker regulations to receive unproven stem cell therapies not approved in their home country
- (d) The export of stem cell products from developing to developed countries
Stem cell tourism is a global public health concern — patients with incurable conditions (ASD, SCI, Parkinson's, cancer) are lured to clinics in countries with weak oversight to pay for unproven therapies. Common destinations include China, Mexico, Ukraine, Germany, Thailand. Patients pay $20,000–$50,000 for treatments with no clinical evidence. Cases of death, tumour formation, and worsened conditions have been documented. The Supreme Court 2026 ruling is significant because it also targets India-based clinics offering such unproven therapies domestically — closing the domestic "stem cell tourism" loophole.
Q6. Which of the following diseases is currently treated using APPROVED stem cell therapy in India?
1. Thalassaemia
2. Autism Spectrum Disorder
3. Sickle Cell Disease
4. Parkinson's Disease
1. Thalassaemia
2. Autism Spectrum Disorder
3. Sickle Cell Disease
4. Parkinson's Disease
- (a) 1 and 3 only
- (b) 1, 2 and 3 only
- (c) 1, 2 and 3
- (d) 1, 2, 3 and 4
Only 1 and 3 are APPROVED. Thalassaemia and Sickle Cell Disease are treated with allogeneic haematopoietic stem cell transplantation (bone marrow transplant) — both are in the list of 32 NMC-approved conditions. Autism (2) is BANNED by Supreme Court Jan 2026. Parkinson's (4) is under Phase I/II clinical trials only (2025 safety data published) — not yet approved. The key distinction: approval means evidence from clinical trials + regulatory clearance + proven safety & efficacy. Research/trials ≠ approved.
⚡ Quick Revision — Stem Cell Therapy Summary
| Topic | Key Facts to Remember |
|---|---|
| Stem Cell — 2 Properties | Self-renewal (copy itself) + Differentiation (become any specialised cell). "Blank recruits" of the body. |
| Potency Ladder | Totipotent (zygote, entire organism) > Pluripotent (ESC/iPSC, 200+ cell types) > Multipotent (Adult HSC, related cells) > Unipotent (one cell type only) |
| Embryonic (ESC) | From IVF blastocyst (5-day embryo). Pluripotent. Controversial — destroys embryo. Research only in India. |
| Adult (HSC/MSC) | From bone marrow, blood, fat. Multipotent. ✅ ONLY APPROVED clinical therapy = HSC transplant for blood diseases (leukaemia, thalassaemia, sickle cell, aplastic anaemia). |
| iPSC | Adult cells (skin/blood) reprogrammed in lab using Yamanaka factors. Pluripotent. No embryo needed. Nobel 2012 — Yamanaka & Gurdon. iPSC published 2006. Future: Parkinson's, AMD, diabetes. Present: research + early trials. |
| Cord Blood | Umbilical cord blood = HSC source. Used like bone marrow transplant. India: LifeCell, Cordlife. ICMR wants PUBLIC cord blood banks. |
| India Regulation | NGSCR 2017/2025 (ICMR+DBT) · New Drugs Rules 2019 (CDSCO) · NMC advisory March 2026: 32 diseases only. Anything else = clinical trial or illegal. |
| SC Jan 2026 Ruling | Yash Charitable Trust v. UoI. Stem cell for ASD = banned outside trials = malpractice. Consent ≠ justification for unproven treatment. Govt to create dedicated regulatory body. |
| Stem Cell Tourism | Patients travel for unproven therapies. Exploits desperate families. Documented deaths. ISSCR has global guidelines against it. India is source + destination. |
| Key Challenges | Teratoma risk (tumour formation) · Immune rejection · Cost (BMT = ₹15–40 lakh) · Embryo ethics · Exploitation of patients · Regulatory gaps across countries |
| UPSC Scheme Links | National Sickle Cell Anaemia Elimination Mission · BIRSA 101 (CRISPR gene therapy using HSCs as vehicle — gene + stem cell combined approach) · Ayushman Bharat (cost of BMT) · National Biopharma Mission / BIRAC (biomedical R&D funding) |
🚨 5 UPSC Traps — Stem Cell Therapy:
Trap 1 — "Bone marrow transplant ≠ stem cell therapy" → WRONG! Bone marrow transplant IS stem cell therapy — specifically Haematopoietic Stem Cell Transplantation (HSCT). It is the OLDEST and ONLY widely approved stem cell therapy. When UPSC asks "which stem cell therapies are widely used?" — the answer is bone marrow transplant (for leukaemia, thalassaemia, etc). All others are experimental. UPSC 2012 PYQ directly tested this.
Trap 2 — "iPSCs require embryo destruction" → WRONG! iPSCs are made from adult cells (skin/blood) reprogrammed in the lab — this is their key advantage! NO embryo is needed. This is why Yamanaka's 2006 discovery won the Nobel Prize 2012 (shared with John B. Gurdon) — it gave science a pluripotent stem cell without ethical controversy. UPSC frequently tests this distinction to catch students who confuse iPSC with ESC.
Trap 3 — "Autologous stem cell therapy has NO rejection risk" → PARTIALLY WRONG! Autologous therapy uses the patient's own cells → very low, but not zero rejection risk. There can still be immune reactions to the manipulation process or delivery vehicle. In contrast, allogeneic (donor) therapy has HIGH rejection risk requiring HLA matching and immunosuppression. "No risk" is an overstatement UPSC will penalise.
Trap 4 — "Supreme Court banned ALL stem cell therapy in India (2026)" → WRONG! The Court banned stem cell therapy SPECIFICALLY for Autism Spectrum Disorder outside approved clinical trials. The NMC advisory restricted routine clinical use to 32 approved conditions (which INCLUDE bone marrow transplants). Approved therapies are still permitted. The ban is on unproven experimental therapies offered as routine clinical services.
Trap 5 — "Embryonic stem cells are the most powerful" → INCOMPLETE! Embryonic stem cells are PLURIPOTENT — not the most powerful. TOTIPOTENT cells (the fertilised egg/zygote and early cleavage cells) are the most powerful — they can form EVERY cell including the placenta. ESCs (from the blastocyst stage) cannot form the placenta — they are pluripotent, not totipotent. This potency distinction is a classic UPSC trick.
Trap 1 — "Bone marrow transplant ≠ stem cell therapy" → WRONG! Bone marrow transplant IS stem cell therapy — specifically Haematopoietic Stem Cell Transplantation (HSCT). It is the OLDEST and ONLY widely approved stem cell therapy. When UPSC asks "which stem cell therapies are widely used?" — the answer is bone marrow transplant (for leukaemia, thalassaemia, etc). All others are experimental. UPSC 2012 PYQ directly tested this.
Trap 2 — "iPSCs require embryo destruction" → WRONG! iPSCs are made from adult cells (skin/blood) reprogrammed in the lab — this is their key advantage! NO embryo is needed. This is why Yamanaka's 2006 discovery won the Nobel Prize 2012 (shared with John B. Gurdon) — it gave science a pluripotent stem cell without ethical controversy. UPSC frequently tests this distinction to catch students who confuse iPSC with ESC.
Trap 3 — "Autologous stem cell therapy has NO rejection risk" → PARTIALLY WRONG! Autologous therapy uses the patient's own cells → very low, but not zero rejection risk. There can still be immune reactions to the manipulation process or delivery vehicle. In contrast, allogeneic (donor) therapy has HIGH rejection risk requiring HLA matching and immunosuppression. "No risk" is an overstatement UPSC will penalise.
Trap 4 — "Supreme Court banned ALL stem cell therapy in India (2026)" → WRONG! The Court banned stem cell therapy SPECIFICALLY for Autism Spectrum Disorder outside approved clinical trials. The NMC advisory restricted routine clinical use to 32 approved conditions (which INCLUDE bone marrow transplants). Approved therapies are still permitted. The ban is on unproven experimental therapies offered as routine clinical services.
Trap 5 — "Embryonic stem cells are the most powerful" → INCOMPLETE! Embryonic stem cells are PLURIPOTENT — not the most powerful. TOTIPOTENT cells (the fertilised egg/zygote and early cleavage cells) are the most powerful — they can form EVERY cell including the placenta. ESCs (from the blastocyst stage) cannot form the placenta — they are pluripotent, not totipotent. This potency distinction is a classic UPSC trick.
